Loading stock data…
PTGX
$98.37-0.60 (-0.61%)
Market ClosedLast close May 1
Protagonist Therapeutics, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Protagonist Therapeutics, Inc. in the Healthcare sector is trading at $98.37. The stock is currently near its 52-week high of $107.84, remaining 23.3% above its 200-day moving average. Technical signals show neutral RSI of 52 and bearish MACD signal, explaining why PTGX maintains its current momentum and trend strength. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 52) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$98.37
Potential Upside
5%
Whystock Fair Value$103.29
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus12 analysts
Mean target$113.33+15.2%
Range$97.00 – $125.00
Fundamentals
Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and ol...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$6.74B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.11
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-21.17%
Volume
Today's trading volume
308,297
Recent News
Protagonist Therapeutics Inc. (PTGX): Billionaire Joe Edelman Likes This Stock
We just covered the Billionaire Joe Edelman’s 10 Stock Picks with Huge Upside Potential and Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ranks 10th on this list. Elite investors have been positioning themselves in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) stock as the firm transforms from a clinical-stage biotech to a high-margin commercial royalty engine. An important reason for interest […]
High Growth Tech Stocks To Watch In US April 2026
The United States market has remained flat over the past week but has experienced a significant 30% increase over the past year, with earnings projected to grow by 16% annually. In this context, identifying high growth tech stocks involves looking for companies that demonstrate strong potential for sustained revenue expansion and innovation in a dynamic economic environment.
How to Play J&J Stock Post a Beat-and-Raise Performance in Q1
JNJ beats Q1 estimates and lifts guidance, but Stelara's patent loss looms. Can pipeline strength and new drugs sustain its growth momentum?
Growth vs. Stability: Lilly and J&J's 2026 Investment Face-Off
JNJ edges out LLY in a tight pharma showdown, backed by stronger valuation and stock performance despite Lilly's explosive GLP-1-driven growth.
Is Protagonist Therapeutics (PTGX) Still Attractive After A 133% One-Year Share Price Surge
If you are wondering whether Protagonist Therapeutics at around US$103.78 is still reasonably priced or already running ahead of itself, the valuation story is where your attention should be. The stock shows returns of 4.9% over 7 days, 13.5% over 30 days, 19.0% year to date, 133.5% over 1 year and roughly 5x over 3 years. These figures raise fair questions about how much of the story is already reflected in the price. Recent headlines around Protagonist Therapeutics have focused on its...